Polimedica Centrum Badan Profilaktyki I Leczenia Sp. z o.o.

The centre is running a study on heart failure with mildly reduced or preserved ejection fraction and systemic inflammation, testing a new anti‑inflammatory agent.

• Evaluation of ziltivekimab as a once‑monthly subcutaneous injection
• Measurement of cardiovascular death and heart‑failure events as primary outcomes
• Integration with standard of care for HFmrEF/HFpEF patients

The trial aims to reduce serious cardiac events in patients whose heart function is compromised by inflammation, reflecting the site’s strength in cardiovascular disease research.

A parallel investigation focuses on asthma, comparing two single‑inhaler regimens to improve symptom control over a twelve‑month period.

• Comparison of Trimbow triple therapy versus Foster dual therapy
• Use of the Asthma Control Questionnaire‑5 to assess treatment effectiveness
• Emphasis on long‑term safety and patient‑reported outcomes

This study highlights Polimedica Centrum Badan Profilaktyki I Leczenia’s commitment to advancing respiratory care and offering better inhaled options for people living with asthma.